Summary
Vertex Pharmaceuticals Inc. filed an 8-K/A amendment on January 30, 2014, to provide previously omitted pro forma financial information related to the deconsolidation of Alios. This filing supplements an earlier 8-K report and is primarily for informational purposes, offering a glimpse into Vertex's historical financial performance adjusted for this significant accounting event. The provided pro forma financial statements include condensed consolidated statements of operations for the nine months ended September 30, 2013, and for the full year ended December 31, 2012. Additionally, a pro forma condensed consolidated balance sheet as of September 30, 2013, is included. Investors should review these documents to understand the financial impact of Alios no longer being consolidated under Vertex's reporting.
Key Highlights
- 1Vertex Pharmaceuticals filed an 8-K/A amendment on January 30, 2014.
- 2The amendment provides pro forma financial information that was not included in the original 8-K filing.
- 3The pro forma information relates to the deconsolidation of Alios.
- 4This filing is an supplement to an 8-K filed on January 29, 2014.
- 5Included are unaudited pro forma condensed consolidated statements of operations for the nine months ended September 30, 2013, and the year ended December 31, 2012.
- 6An unaudited pro forma condensed consolidated balance sheet as of September 30, 2013, is also provided.
- 7The pro forma data is for informational purposes to show historical results adjusted for the deconsolidation of Alios.